Triple negative breast cancer (TNBC) is characterized by the lack of estrogen receptor, progesterone receptor, and HER2 and cannot be treated with the available hormone therapies and receptor targeted treatments. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.